Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Reason for performing study: The use of firocoxib in horses and its ability to affect performance and potential to allow a horse to compete when it otherwise should not, necessitates establishing appropriate withdrawal time guidelines prior to performance. Objectives: To describe plasma concentrations and characterise the pharmacokinetics of 3 firocoxib formulations following multiple administrations of the label dose, with respect to recommended plasma thresholds for performance horses. Study design: Balanced 3-way crossover prospective study. Methods: Nine healthy mature horses were administered firocoxib injectable solution (0.09mg/kg bwt i.v. s.i.d. for 5 days), firocoxib paste (0.1mg/kg bwt per os s.i.d. for 14 days) and firocoxib tablets (57mg s.i.d. for 14 days). Blood samples were collected at Time 0 and at various times post drug administration until plasma concentrations were below the limit of detection of the assay. Plasma samples were analysed using liquid chromatography-mass spectrometry and data analysed using noncompartmental analysis. Results: The mean plasma half-life was 1.64 ± 0.737, 1.70 ± 0.800 and 1.73 ± 0.767 days for injectable, paste and tablet formulations, respectively. Plasma concentrations fell below the Racing Medication and Testing Consortium's recommended threshold for racehorses (20ng/ml) by 7 days post administration of the final dose for all formulations. Plasma concentrations never exceeded the threshold concentration (240ng/ml) for horse competing in US Equestrian Federation events for any of the formulations. Conclusions: This study extends current knowledge regarding the pharmacokinetics of firocoxib and provides information that can be used to establish appropriate withdrawal time guidelines following multiple administrations, with respect to already established plasma regulatory threshold concentrations.

Original languageEnglish (US)
Pages (from-to)734-738
Number of pages5
JournalEquine Veterinary Journal
Volume46
Issue number6
DOIs
StatePublished - Nov 1 2014

Fingerprint

pharmacokinetics
Horses
Pharmacokinetics
horses
Ointments
racehorses
Tablets
dosage
prospective studies
liquid chromatography
drug therapy
half life
Guidelines
detection limit
Injections
experimental design
firocoxib
mass spectrometry
sampling
drugs

Keywords

  • Firocoxib
  • Horse
  • Performance horse
  • Pharmacokinetics
  • Racehorse
  • Threshold

ASJC Scopus subject areas

  • Equine

Cite this

@article{4d10179b7bba4b0985009d793eb208f7,
title = "Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses",
abstract = "Reason for performing study: The use of firocoxib in horses and its ability to affect performance and potential to allow a horse to compete when it otherwise should not, necessitates establishing appropriate withdrawal time guidelines prior to performance. Objectives: To describe plasma concentrations and characterise the pharmacokinetics of 3 firocoxib formulations following multiple administrations of the label dose, with respect to recommended plasma thresholds for performance horses. Study design: Balanced 3-way crossover prospective study. Methods: Nine healthy mature horses were administered firocoxib injectable solution (0.09mg/kg bwt i.v. s.i.d. for 5 days), firocoxib paste (0.1mg/kg bwt per os s.i.d. for 14 days) and firocoxib tablets (57mg s.i.d. for 14 days). Blood samples were collected at Time 0 and at various times post drug administration until plasma concentrations were below the limit of detection of the assay. Plasma samples were analysed using liquid chromatography-mass spectrometry and data analysed using noncompartmental analysis. Results: The mean plasma half-life was 1.64 ± 0.737, 1.70 ± 0.800 and 1.73 ± 0.767 days for injectable, paste and tablet formulations, respectively. Plasma concentrations fell below the Racing Medication and Testing Consortium's recommended threshold for racehorses (20ng/ml) by 7 days post administration of the final dose for all formulations. Plasma concentrations never exceeded the threshold concentration (240ng/ml) for horse competing in US Equestrian Federation events for any of the formulations. Conclusions: This study extends current knowledge regarding the pharmacokinetics of firocoxib and provides information that can be used to establish appropriate withdrawal time guidelines following multiple administrations, with respect to already established plasma regulatory threshold concentrations.",
keywords = "Firocoxib, Horse, Performance horse, Pharmacokinetics, Racehorse, Threshold",
author = "Knych, {Heather K} and Stanley, {Scott D} and Rick Arthur and Mitchell, {M. M.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1111/evj.12211",
language = "English (US)",
volume = "46",
pages = "734--738",
journal = "Equine veterinary journal. Supplement",
issn = "2042-3306",
publisher = "British Equine Veterinary Association",
number = "6",

}

TY - JOUR

T1 - Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses

AU - Knych, Heather K

AU - Stanley, Scott D

AU - Arthur, Rick

AU - Mitchell, M. M.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Reason for performing study: The use of firocoxib in horses and its ability to affect performance and potential to allow a horse to compete when it otherwise should not, necessitates establishing appropriate withdrawal time guidelines prior to performance. Objectives: To describe plasma concentrations and characterise the pharmacokinetics of 3 firocoxib formulations following multiple administrations of the label dose, with respect to recommended plasma thresholds for performance horses. Study design: Balanced 3-way crossover prospective study. Methods: Nine healthy mature horses were administered firocoxib injectable solution (0.09mg/kg bwt i.v. s.i.d. for 5 days), firocoxib paste (0.1mg/kg bwt per os s.i.d. for 14 days) and firocoxib tablets (57mg s.i.d. for 14 days). Blood samples were collected at Time 0 and at various times post drug administration until plasma concentrations were below the limit of detection of the assay. Plasma samples were analysed using liquid chromatography-mass spectrometry and data analysed using noncompartmental analysis. Results: The mean plasma half-life was 1.64 ± 0.737, 1.70 ± 0.800 and 1.73 ± 0.767 days for injectable, paste and tablet formulations, respectively. Plasma concentrations fell below the Racing Medication and Testing Consortium's recommended threshold for racehorses (20ng/ml) by 7 days post administration of the final dose for all formulations. Plasma concentrations never exceeded the threshold concentration (240ng/ml) for horse competing in US Equestrian Federation events for any of the formulations. Conclusions: This study extends current knowledge regarding the pharmacokinetics of firocoxib and provides information that can be used to establish appropriate withdrawal time guidelines following multiple administrations, with respect to already established plasma regulatory threshold concentrations.

AB - Reason for performing study: The use of firocoxib in horses and its ability to affect performance and potential to allow a horse to compete when it otherwise should not, necessitates establishing appropriate withdrawal time guidelines prior to performance. Objectives: To describe plasma concentrations and characterise the pharmacokinetics of 3 firocoxib formulations following multiple administrations of the label dose, with respect to recommended plasma thresholds for performance horses. Study design: Balanced 3-way crossover prospective study. Methods: Nine healthy mature horses were administered firocoxib injectable solution (0.09mg/kg bwt i.v. s.i.d. for 5 days), firocoxib paste (0.1mg/kg bwt per os s.i.d. for 14 days) and firocoxib tablets (57mg s.i.d. for 14 days). Blood samples were collected at Time 0 and at various times post drug administration until plasma concentrations were below the limit of detection of the assay. Plasma samples were analysed using liquid chromatography-mass spectrometry and data analysed using noncompartmental analysis. Results: The mean plasma half-life was 1.64 ± 0.737, 1.70 ± 0.800 and 1.73 ± 0.767 days for injectable, paste and tablet formulations, respectively. Plasma concentrations fell below the Racing Medication and Testing Consortium's recommended threshold for racehorses (20ng/ml) by 7 days post administration of the final dose for all formulations. Plasma concentrations never exceeded the threshold concentration (240ng/ml) for horse competing in US Equestrian Federation events for any of the formulations. Conclusions: This study extends current knowledge regarding the pharmacokinetics of firocoxib and provides information that can be used to establish appropriate withdrawal time guidelines following multiple administrations, with respect to already established plasma regulatory threshold concentrations.

KW - Firocoxib

KW - Horse

KW - Performance horse

KW - Pharmacokinetics

KW - Racehorse

KW - Threshold

UR - http://www.scopus.com/inward/record.url?scp=84911807545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911807545&partnerID=8YFLogxK

U2 - 10.1111/evj.12211

DO - 10.1111/evj.12211

M3 - Article

C2 - 24393414

AN - SCOPUS:84911807545

VL - 46

SP - 734

EP - 738

JO - Equine veterinary journal. Supplement

JF - Equine veterinary journal. Supplement

SN - 2042-3306

IS - 6

ER -